Corvus Pharmaceuticals (CRVS) AI Stock Analysis

• Market Cap: $516.80M
• Dividend Yield: N/A
• Average Volume (3M): 1.50M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.25
• Revenue Growth: N/A
• EPS Growth: 79.27%
• Country: US
• Employees: 31
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.12
• Shares Outstanding: 74,681,870
• 10 Day Avg. Volume: 1,344,937
• 30 Day Avg. Volume: 1,497,251
• PEG Ratio: -0.06
• Price to Book (P/B): 10.02
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -12.83
• Enterprise Value/Market Cap: 1.06
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -14.23
• 1Y Price Target: $13.33
• Price Target Upside: 92.63% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 50 Neutral
• Price Target: $7.50 ▲(8.38% Upside)

The score is held back primarily by weak financial performance (pre-revenue with ongoing losses and material cash burn). The latest earnings call provides support via improved quarterly loss trends, a cash runway into Q4 2026, and meaningful clinical trial progress, but near-term technical momentum is soft and valuation is constrained by negative earnings.

Positive Factors

Clinical Advancements

The 39% objective response rate in Phase 1 trials for T-cell lymphoma shows strong potential for socalitinib, enhancing Corvus's drug pipeline and market prospects.

Cash Position

A strong cash position provides operational runway until Q1 2026, supporting ongoing R&D and strategic initiatives without immediate financial strain.

Strategic Leadership

The appointment of a new director enhances governance and oversight, potentially improving operational effectiveness and stakeholder confidence.

Negative Factors

Increasing Net Loss

Rising net losses indicate financial strain and highlight the need for successful commercialization of drug candidates to achieve profitability.

R&D Expenses

Higher R&D expenses reflect increased investment in drug development but also contribute to financial losses, stressing the importance of successful trial outcomes.

Cash Flow Challenges

Negative cash flows indicate reliance on external financing, posing risks to sustainability if clinical advancements do not lead to revenue generation.

Corvus Pharmaceuticals Business Overview & Revenue Model

Company Description

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.

How the Company Makes Money

Corvus Pharmaceuticals generates revenue primarily through the development and potential commercialization of its immuno-oncology drug candidates. The company typically seeks to advance its drug candidates through clinical trials and may enter into licensing agreements or partnerships with larger pharmaceutical companies to co-develop or market these treatments. Additionally, Corvus may receive milestone payments and royalties from its partners based on the success and sales of the developed drugs. Grants and research funding from governmental or non-profit organizations can also contribute to its revenue streams.

Corvus Pharmaceuticals Financial Statement Overview

Summary

Corvus Pharmaceuticals is facing significant financial challenges with no revenue and ongoing losses. The balance sheet is stable with low leverage, but declining equity poses risks. Cash flow issues persist, driven by negative operational results and reliance on financing activities for liquidity.

Income Statement

Corvus Pharmaceuticals has consistently reported zero revenue over the years, indicating a lack of commercial success or product launches. The company also reports significant net losses, with no visible improvement in net profit margin. The EBIT and EBITDA margins are non-existent due to the absence of revenue, highlighting ongoing operational challenges.

Balance Sheet

The balance sheet shows a relatively low debt-to-equity ratio, suggesting limited leverage with a Total Debt of $1.12 million against a Stockholders' Equity of $32.57 million. Despite this, the equity ratio has declined, pointing to potential risks as liabilities increase. The company has a declining stockholders' equity over the years, indicating potential financial vulnerability.

Cash Flow

The cash flow statement reveals negative operating and free cash flows, demonstrating cash burn with no revenue inflows. Despite a recent increase in financing cash flow, the reliance on external financing is a concern. Free cash flow remains negative, reflecting continuous operational cash challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00	-632.00K
EBITDA	-38.34M	-27.46M	-23.26M	-32.20M	-38.17M	-5.36M
Net Income	-15.07M	-62.29M	-27.03M	-41.31M	-43.24M	-6.00M
Balance Sheet
Total Assets	80.47M	68.91M	45.55M	68.24M	109.45M	85.53M
Cash, Cash Equivalents and Short-Term Investments	65.69M	51.96M	27.15M	42.30M	69.45M	44.26M
Total Debt	1.01M	1.12M	1.37M	2.60M	3.65M	2.31M
Total Liabilities	8.71M	36.34M	6.87M	12.13M	12.29M	13.38M
Stockholders Equity	71.77M	32.57M	38.68M	56.12M	97.16M	72.15M
Cash Flow
Free Cash Flow	-32.22M	-25.42M	-23.97M	-27.29M	-36.72M	-34.85M
Operating Cash Flow	-32.07M	-25.42M	-23.93M	-27.02M	-36.72M	-34.78M
Investing Cash Flow	-24.76M	-27.48M	15.54M	-23.28M	21.56M	44.77M
Financing Cash Flow	55.02M	49.03M	7.86M	0.00	62.16M	1.31M

Corvus Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 6.92
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRVS, the sentiment is Negative. The current price of 6.92 is below the 20-day moving average (MA) of 7.62, below the 50-day MA of 8.04, and above the 200-day MA of 5.55, indicating a neutral trend. The MACD of -0.34 indicates Positive momentum. The RSI at 38.57 is Neutral, neither overbought nor oversold. The STOCH value of 32.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CRVS.

Corvus Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RIGL	78 Outperform	$807.73M	7.22	220.06%	―	79.13%	2798.12%
ATXS	54 Neutral	$740.96M	-6.04	-43.15%	―	―	-2.74%
RCKT	52 Neutral	$419.90M	-1.73	-74.88%	―	―	18.39%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ALT	51 Neutral	$425.72M	-3.82	-52.61%	―	-61.54%	31.25%
CRVS	50 Neutral	$516.80M	-12.94	-35.82%	―	―	79.27%
NGNE	50 Neutral	$289.35M	-4.22	-42.25%	―	-100.00%	1.47%

Corvus Pharmaceuticals Corporate Events

Corvus Pharmaceuticals Appoints David Moore as Director

On October 2, 2025, Corvus Pharmaceuticals appointed David Moore as a Class III director to its Board, with his term set to expire in 2028. Mr. Moore will also serve on the Compensation and Nominating Committees, receiving compensation through an annual retainer, stock options, and additional cash for his committee roles, aligning with the company’s non-employee director compensation program.

The most recent analyst rating on (CRVS) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Corvus Pharmaceuticals stock, see the CRVS Stock Forecast page.